Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks highlights positive Earnings ESPs for United Therapeutics and Eli Lilly ahead of their upcoming reports: UTHR’s most accurate estimate is $6.70 per share versus a $6.38 consensus (+4.99%), with results due November 4, 2026; LLY’s is $9.95 versus $9.83 (+1.21%), ahead of an October 29, 2026 report. Both carry a Zacks Rank #3 (Hold); the article presents positive ESPs as indicating a better chance of beating estimates, not as reported earnings results.

Analysis

This is a revision-momentum screen, not new evidence of improving fundamentals. A positive gap between a recent estimate and consensus can flag information flow, but it neither establishes the likely size of a beat nor predicts the stock’s reaction: shares respond to results versus buy-side expectations and forward guidance, not just reported EPS. The cited backtest is promotional evidence; before relying on it, verify its universe, turnover, transaction costs, and out-of-sample performance.

The signal is more notable for United Therapeutics than for Eli Lilly on the figures provided, but neither estimate gap is enough to justify an unhedged pre-earnings position. For UTHR, check whether revisions are broad-based and supported by product-level demand and guidance; a beat without durable outlook improvement may not sustain a move. For LLY, a small positive revision could be overwhelmed by expectations embedded in valuation and any commentary on demand, supply, or the forward outlook. These are distinct businesses, so a pair trade between them is not a clean hedge.

Near term, estimate changes and positioning can drive volatility into each report. Over the next 1–3 months, guidance and subsequent analyst revisions matter more than the initial surprise. The contrarian point is that the article’s “beat probability” framing omits the more important hurdle: whether the beat and outlook exceed what investors already expect. A flat or negative share reaction despite an EPS beat would falsify the simple positive-ESP trading thesis.

Key Decisions for Investors

• No immediate directional trade based on this article alone. Before either report, verify estimate-revision breadth and recency, prior earnings reaction, implied volatility, and the market’s expectations for guidance; those inputs are not supplied.
• Treat UTHR as the higher-priority event watch, not an automatic long: consider a defined-risk bullish position only if revisions continue to rise and the option premium does not make the required move uneconomic. Reduce or avoid exposure if revisions reverse or company guidance weakens.
• For LLY, require confirmation from forward-demand and supply commentary expectations before taking pre-earnings risk; a modest estimate edge alone is vulnerable to a sell-the-news reaction. Avoid using UTHR as a hedge because the companies do not share a sufficiently direct operating exposure.
• After each release, favor the stock only if the result is accompanied by constructive forward guidance and continued upward revisions. A beat followed by weaker outlook, or a negative price reaction that persists through the next session, invalidates the earnings-surprise thesis.